Hinrich Gronemeyer is a Research Director at the GBMC in Strasbourg-Illkirch. Trained as a chemist, he did his Ph.D. degree in biochemistry at the RUB Bochum, Germany, and joined as a Postdoc the team of Pierre Chambon (Strasbourg, France), where he became the Head of the Cell Biology and Signal Transduction Department and Cancer Biology Department in the newly founded IGBMC. He is the Research Director (Exceptional Class) of the French National Institute of Health and Medical Research (INSERM). Moreover, he had extensive collaborations with the pharmaceutical industry (Bristol Myers Squibb, Roussel-Uclaf, Schering AG, etc.). He has long-standing experience in the field of nuclear receptors, with a particular focus on the functional characterization and modulation of retinoid receptors in health and disease. His 200 and more publications received an average citation of more than 83 and an h-factor of 60 (status October 2011); Many of his papers are among the top 1% cited. His team has contributed to pioneering work on the structural and functional analysis of nuclear receptors and signal propagation to the transcription and epigenetic machineries and its modulation by the design of ligands with different functionalities. Presently, his team studies nuclear receptor action from a systems biology perspective to reveal the temporal regulation of gene networks and program diversification by epigenetic actors. The basic research done in his group has been always been linked to disease; in this respect, several novel paradigms for cancer therapy have been developed, including the recognition of cancer-selective apoptosis in retinoid and epigenetic drug therapies or the recently reported autonomous rexinoid apoptosis. Over the recent years, his team has developed and optimized technologies to facilitate genome-wide disease-relevant transcription factor and epigenomics studies, including ultra-small sample sizes, and to comprehensively investigate the rapidly expanding RNA universe.
Biography Updated on 29 November 2011